Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
about
Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic ReviewValidating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluations.Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committeeCharacteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial.Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerValidation of the Hospital Episode Statistics Outpatient Dataset in England.Using routinely recorded data in the UK to assess outcomes in a randomised controlled trial: The Trials of Access.Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP).Recommandations de l’Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate.A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial.Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial
P2860
Q26748873-E555C0EB-BD84-4F76-89B4-AE8BE967A91AQ31088071-914B03FC-B046-4700-B31E-0D7716FA4EB3Q35547542-EC24BE1B-EB58-44EF-9015-2E1DB2EFE3B4Q36274875-DDD5AFAD-4C7A-43E1-8698-1DD0AC0E9057Q37061367-22CB85ED-E278-4636-A7B1-C17F79F3CD2BQ37340801-03526C6F-C783-479E-826F-FFAF603F8F31Q37468498-AE633D1D-C860-4E9C-BB3B-4F87E6EB4633Q38589645-EBD72EB9-816B-4072-BDCB-D129FED73B98Q38611334-3B84DA3A-CF83-4539-BB37-A7788E79FB95Q46118170-92F547A0-363F-4F90-BF48-C070F394EA7DQ47123251-0E9D5299-9EAB-41D6-9390-7F3B13976762Q47232656-9E55C96E-A86B-4947-9C18-0D340D09FAB6Q57101962-E2208C5A-AA65-4078-BDF9-D3CB53BEA26F
P2860
Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Design and preliminary recruit ...... ting for Prostate cancer (CAP)
@ast
Design and preliminary recruit ...... ting for Prostate cancer (CAP)
@en
type
label
Design and preliminary recruit ...... ting for Prostate cancer (CAP)
@ast
Design and preliminary recruit ...... ting for Prostate cancer (CAP)
@en
prefLabel
Design and preliminary recruit ...... ting for Prostate cancer (CAP)
@ast
Design and preliminary recruit ...... ting for Prostate cancer (CAP)
@en
P2093
P2860
P50
P356
P1476
Design and preliminary recruit ...... ting for Prostate cancer (CAP)
@en
P2093
C Metcalfe
E L Turner
J A C Sterne
J L Donovan
P2860
P2888
P304
P356
10.1038/BJC.2014.242
P407
P577
2014-05-27T00:00:00Z
P5875
P6179
1029223828